All eyes are on Vertex’s two Phase 3 trials into a triple therapy for cystic fibrosis (CF), in the meantime, however, it’s just received the nod from the FDA for its two therapy combination treatment in the same area.
Symdeko, as the treatment is called, combines existing treatment Kalydeco (ivacafto) with tezacaftor. The combination treatment was shown to improve lung function, reduced pulmonary exacerbations, increase BMI (though in a non-statistically significant manner) and patients reported fewer symptoms, such as coughing and wheezing, in a Phase 3 trial.
